Anti-inflammatory drug found to help adults with severe schizophrenia
- Schizophrenia affects 35 million adults worldwide each year
- First study to find that monoclonal antibody drug can provide symptom relief to people with schizophrenia and inflammation
- Randomised control trial
- Opens pathways towards personalised treatment of schizophrenia
Research conducted at Neuroscience Research Australia has found that an injection of an anti-flammatory biological known as Canakinumab in patients with schizophrenia and elevated inflammation brought about a decrease in psychotic symptom severity and inflammation. The research was published in Brain, Behavior, and Immunity.
“Our study is the first clinical trial of anti-inflammatories for people with schizophrenia who also have an elevated inflammation status,” says Professor Cyndi Shannon Weickert, lead author on the study and Senior Professor at Neuroscience Research Australia.
Read more: Anti-inflammatory drug found to help adults with severe schizophrenia
Latest News & Events
Opinion: Pilot program, Keep Quitting in Mind, found one in nine people who smoke and have a severe mental illness quit the habit
January 23, 2024A smoking cessation pilot program Keep Quitting in Mind – designed specifically for people living with severe mental illness – has helped one in nine participants quit smoking, demonstrating the positive impacts that are possible for an at-risk yet typically overlooked population group.
Promising results for smoking cessation program as one in nine participants quit the habit
January 23, 2024A smoking cessation program, Keep Quitting in Mind (KQIM), for people living with mental illness has resulted in one in nine participants quitting the habit and many others reducing their daily smoking by half.
Launch of world-first guidelines for the treatment of first responders with PTSD
January 23, 2024Black Dog Institute and UNSW Sydney launched new guidelines for the management of PTSD among emergency service workers on Thursday, 21 March in NSW Parliament with Emergency Management Minister Jihad Dib and Mental Health Minister Rose Jackson.
Mindgardens Neuroscience Network acknowledges the Traditional Owners of Country throughout Australia and recognises their continuing connection to land, waters and community. We pay our respect to them and their cultures, and to Elders past, present and emerging.
We acknowledge the voices of people with lived experience, their carers, families and kinship groups. We recognise the expertise acquired through living with a mental health, drug and alcohol or neurological disorder and acknowledge those who care for people on their recovery journey. We place lived experience at the heart of all that we do.
Launch of world-first guidelines for the treatment of first responders with PTSD
Brings together the strengths of four founding organisations
